4D Pharma PLC (LBPS)
US35085K1097 - ADR
| 2021 (2021-12-31) | 2020 (2020-12-31) | 2019 (2019-12-31) | 2018 (2018-12-31) | 2017 (2017-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash | N/A | N/A | N/A | N/A | N/A | |||
| Cash Equivalents | 15.50M | 8.78M | 3.84M | 16.05M | 11.87M | |||
| Marketable Securities | N/A | N/A | 0.00 | 10.17M | 38.13M | |||
| Receivables | 7.56M | 4.44M | 6.12M | 5.39M | 4.31M | |||
| Inventories | 270.00K | 290.00K | 200.00K | 290.00K | 253.00K | |||
| Other Current Assets | 2.17M | 3.22M | 1.12M | 1.25M | 3.24M | |||
| Total Current Assets | 25.49M | 16.73M | 11.27M | 33.16M | 57.80M | |||
| Non-Current Assets | ||||||||
| PPE Net | 3.56M | 4.49M | 5.16M | 4.87M | 5.21M | |||
| Investments And Advances | N/A | N/A | N/A | N/A | N/A | |||
| Intangibles | 4.53M | 4.61M | 4.80M | 4.99M | 5.28M | |||
| Total Non-Current Assets | 17.45M | 18.69M | 19.34M | 19.44M | 19.94M | |||
| TOTAL ASSETS | 42.94M | 35.42M | 30.61M | 52.60M | 77.74M | |||
| LIABILITIES | ||||||||
| Current Liabilities | ||||||||
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Current Portion Of LT Debt. | 80.00K | 70.00K | 70.00K | 10.00K | 10.00K | |||
| Accrued Expenses | 2.88M | 1.83M | 4.94M | 1.57M | 2.47M | |||
| Accounts Payable | 1.22M | 3.30M | 1.22M | 1.93M | 1.80M | |||
| Other Current Liabilities | 700.00K | 1.25M | 30.00K | 1.67M | 695.00K | |||
| Total Current Liabilities | 4.89M | 6.45M | 6.26M | 5.18M | 4.98M | |||
| Non-Current Liabilities | ||||||||
| Long Term Debt | 9.85M | 990.00K | 1.04M | 10.00K | 26.00K | |||
| Deferred Taxes/Income | 10.00K | 10.00K | 960.00K | 970.00K | 965.00K | |||
| Other Non-Current Liabilities | 4.99M | N/A | 0.00 | 680.00K | 1.98M | |||
| Total Non-Current Liabilities | 14.85M | 1.00M | 2.01M | 1.66M | 2.97M | |||
| TOTAL LIABILITIES | 19.74M | 7.45M | 8.27M | 6.84M | 7.95M | |||
| SHAREHOLDERS' EQUITY | ||||||||
| Retained Earnings | -162.80M | -109.19M | -86.56M | -62.76M | -39.34M | |||
| Additional Paid In Capital | 185.70M | 136.28M | 108.30M | 108.30M | 108.30M | |||
| Minority Interest | N/A | N/A | N/A | 0.00 | 184.00K | |||
| Common Shares | 450.00K | 330.00K | 160.00K | 160.00K | 164.00K | |||
| Other Shareholders' Equity | -160.00K | 560.00K | 450.00K | 70.00K | 668.00K | |||
| Shares Outstanding | 22.53M | 16.43M | 8.18M | 8.18M | 8.19M | |||
| Tangible Book Value per Share | 0.05 | 0.11 | 0.13 | 0.48 | 0.84 | |||
| Total Shareholders' Equity | 23.20M | 27.97M | 22.34M | 45.76M | 69.79M | |||
| TOTAL LIABILITIES AND EQUITY | 42.94M | 35.42M | 30.61M | 52.60M | 77.74M | |||
| Statistics | ||||||||
| Debt/Equity | 0.42 | 0.04 | 0.05 | 0.00 | 0.00 | |||
| Current Ratio | 5.21 | 2.59 | 1.80 | 6.40 | 11.60 | |||
| Return On Assets (ROA) | -125.66% | -73.29% | -78.63% | -45.04% | -26.30% | |||
| Return On Equity (ROE) | -232.59% | -92.81% | -107.74% | -51.77% | -29.30% | |||
All data in GBP